Brokerages expect that Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) will post $21.54 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Ultragenyx Pharmaceutical’s earnings. The highest sales estimate is $22.77 million and the lowest is $20.20 million. Ultragenyx Pharmaceutical posted sales of $12.79 million during the same quarter last year, which suggests a positive year over year growth rate of 68.4%. The company is expected to issue its next earnings results on Thursday, August 1st.
According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full-year sales of $95.45 million for the current fiscal year, with estimates ranging from $87.10 million to $103.26 million. For the next year, analysts anticipate that the firm will report sales of $197.32 million, with estimates ranging from $142.10 million to $248.64 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($1.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.73) by ($0.09). The company had revenue of $18.17 million during the quarter, compared to analyst estimates of $18.75 million. Ultragenyx Pharmaceutical had a negative return on equity of 51.00% and a negative net margin of 550.30%. The business’s revenue for the quarter was up 70.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.63 earnings per share.
In related news, EVP Karah Herdman Parschauer sold 1,489 shares of the company’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $63.01, for a total value of $93,821.89. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders sold 3,183 shares of company stock worth $201,185. Corporate insiders own 7.80% of the company’s stock.
Several hedge funds have recently bought and sold shares of RARE. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Ultragenyx Pharmaceutical by 8.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,113 shares of the biopharmaceutical company’s stock valued at $216,000 after buying an additional 242 shares during the last quarter. American International Group Inc. raised its holdings in Ultragenyx Pharmaceutical by 0.8% during the 4th quarter. American International Group Inc. now owns 31,456 shares of the biopharmaceutical company’s stock worth $1,368,000 after purchasing an additional 265 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in Ultragenyx Pharmaceutical by 16.6% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,924 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 274 shares during the last quarter. Meeder Asset Management Inc. grew its position in shares of Ultragenyx Pharmaceutical by 321.1% during the 1st quarter. Meeder Asset Management Inc. now owns 598 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 456 shares during the period. Finally, First Mercantile Trust Co. grew its position in shares of Ultragenyx Pharmaceutical by 101.0% during the 1st quarter. First Mercantile Trust Co. now owns 985 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 495 shares during the period.
NASDAQ RARE traded up $1.03 during midday trading on Tuesday, hitting $57.39. The company had a trading volume of 288,579 shares, compared to its average volume of 551,605. The company has a debt-to-equity ratio of 0.03, a quick ratio of 11.60 and a current ratio of 11.77. The firm has a market cap of $3.42 billion, a PE ratio of -7.77 and a beta of 2.17. The stock has a fifty day moving average of $59.37. Ultragenyx Pharmaceutical has a fifty-two week low of $37.44 and a fifty-two week high of $90.98.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.
Read More: Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.